Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Danaher Reports First Quarter 2018 Results

Danaher
Posted on: 22 Apr 18

WASHINGTON, April 19, 2018 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2018. For the quarter ended March 30, 2018, net earnings were $566.6 million, or $0.80 per diluted share which represents a 16.0% year-over-year increase.

Non-GAAP adjusted diluted net earnings per share were $0.99. This represents a 16.5% increase over the comparable 2017 period. For the first quarter 2018, revenues increased 11.5% year-over-year to $4.7 billion, with non-GAAP core revenue growth of 5.5%.

Operating cash flow for the first quarter 2018 was $828.9 million, representing a 48% increase over the comparable 2017 period. Non-GAAP free cash flow for the first quarter 2018 increased 72% year-over-year to $691.4 million, representing a non-GAAP free cash flow to net income conversion ratio for the first quarter 2018 of 122%.

For the second quarter 2018, the Company anticipates that diluted net earnings per share will be in the range of $0.88 to $0.91 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.07 to $1.10.

For the full year 2018, the Company now anticipates that diluted net earnings per share will be in the range of $3.62 to $3.69. The Company now expects its 2018 non-GAAP adjusted diluted net earnings per share to be in the range of $4.38 to $4.45 versus previous guidance of $4.25 to $4.35.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "We are off to an outstanding start in 2018, with the first quarter coming in ahead of our initial expectations. We delivered 5.5% core revenue growth, mid-teens earnings per share growth and free cash flow that increased more than 70% year-on-year. This strong performance was broad-based, with four of our five platforms delivering mid-single digit or better core revenue growth — including 9.5% growth in Diagnostics, which was led by Cepheid. We also announced the acquisition of Integrated DNA Technologies, Inc. ("IDT"), a leading player in the highly attractive genomics consumables segment. We closed the IDT acquisition last week and are excited to welcome the IDT team to Danaher."

Joyce continued, "Our great start to 2018 is a testament to the power of the Danaher Business System, strong execution by the Danaher team and our focus on long-term value creation. Our performance in the quarter — combined with significant opportunities across the portfolio and our solid balance sheet — positions us well for strong performance in 2018 and beyond."

Danaher will discuss its results during its quarterly investor conference call today starting at 8:00 a.m. ET.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 888-882-4478 within the U.S. or by dialing +1 323-794-2149 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's investor conference call (access code 1818726).  A replay of the conference call will be available shortly after the conclusion of the call and until April 26, 2018.  You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations." In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings."

All results in this release reflect only continuing operations unless otherwise noted.

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.  Its family of world class brands has leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial.  With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System.  For more information, please visit www.danaher.com.

NON-GAAP MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures.  Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

FORWARD-LOOKING STATEMENTS

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial performance for the second quarter and full year 2018, the anticipated impact of the IDT acquisition, the Company's opportunities and positioning for 2018 and beyond and any other statements regarding events or developments that we anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to the distributions of each of Fortive Corporation and our communications business), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's decision to leave the EU and changes in U.S. policy stemming from the current administration, such as changes in U.S. trade policies and the reaction of other countries thereto), disruptions relating to man-made and natural disasters, and pension plan costs.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2017 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2018.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

For more information:
www.prnewswire.com/news-releases/danaher-reports-first-quarter-2018-results-300632701.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 22/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.